Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Critical Care
Volume 2017, Article ID 5310768, 3 pages
https://doi.org/10.1155/2017/5310768
Case Report

Dosing of Ertapenem in an Extreme Obesity: A Case Report of 250 kg Patient

1Tartu University Hospital Pharmacy, Tartu, Estonia
2Department of Microbiology, University of Tartu, Tartu, Estonia
3Clinic of Anaesthesiology and Intensive Care, Tartu University Hospital, Tartu, Estonia
4Department of Anaesthesiology and Intensive Care, University of Tartu, Tartu, Estonia
5Institute of Chemistry, University of Tartu, Tartu, Estonia
6Analytical Services International, St George’s University of London, London, UK

Correspondence should be addressed to Jana Lass; ee.mukiniilk@ssal.anaj

Received 26 June 2017; Accepted 7 September 2017; Published 8 October 2017

Academic Editor: Mehmet Doganay

Copyright © 2017 Jana Lass et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Leykin, L. Miotto, and T. Pellis, “Pharmacokinetic considerations in the obese,” Practice & Research Clinical Anaesthesiology, vol. 25, no. 1, pp. 27–36, 2011. View at Google Scholar
  2. A. Perner, A. C. Gordon, D. De Backer et al., “Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy,” Intensive Care Medicine, vol. 42, no. 12, pp. 1958–1969, 2016. View at Publisher · View at Google Scholar
  3. SMPC of ertapenem http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000389/WC500033921.pdf.
  4. M. Chen, A. N. Nafziger, G. L. Drusano, L. Ma, and J. S. Bertino, “Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 4, pp. 1222–1227, 2006. View at Publisher · View at Google Scholar
  5. N. Šoštarič, B. Beović, and M. Matičič, “Ertapenem-associated seizures in a patient without prior CNS disorder or severe renal dysfunction,” International Journal of Clinical Pharmacology and Therapeutics, vol. 52, no. 03, pp. 255–258, 2014. View at Publisher · View at Google Scholar
  6. F. Yılmaz, H. Uslu, and F. Ersoy, “Ertapenem associated with seizures in treatment of pyelonephritis in a chronic peritoneal dialysis patient,” Therapeutic Apheresis and Dialysis, vol. 20, no. 1, pp. 89-90, 2016. View at Publisher · View at Google Scholar
  7. K. Kipper, D. Lonsdale, C. Barker, M. Sharland, and A. Johnston, “Bioanalytical UHPLC-MS/MS method development and validation for measuring commonly used antibiotics in human blood plasma,” in Proceedings of the MSACL 2016 US 8th Annual Conference and Exhibits, Palm Springs, Calif, USA, February 2016.
  8. M. Wittau, S. Paschke, M. Kurlbaum et al., “Population pharmacokinetics and target attainment of ertapenem in plasma and tissue assessed via microdialysis in morbidly obese patients after laparoscopic visceral surgery,” Antimicrobial Agents and Chemotherapy, vol. 61, no. 1, p. e00952-16, 2017. View at Publisher · View at Google Scholar
  9. O. Burkhardt, V. Kumar, D. Katterwe et al., “Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 2, pp. 277–284, 2007. View at Publisher · View at Google Scholar
  10. W. A. Craig, “Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid,” Infectious Disease Clinics of North America, vol. 17, no. 3, pp. 479–501, 2003. View at Publisher · View at Google Scholar
  11. G. L. Drusano, “Prevention of resistance: a goal for dose selection for antimicrobial agents,” Clinical Infectious Diseases, vol. 36, Supplement 1, pp. S42–S50, 2003. View at Publisher · View at Google Scholar
  12. J. A. Roberts, S. K. Paul, M. Akova et al., “Defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically Ill patients?” Clinical Infectious Diseases, vol. 58, pp. 1072–1083, 2014. View at Google Scholar